Methods for the treatment of cancer using coenzyme Q10 combination therapies
Inventors
Narain, Niven Rajin • Sarangarajan, Rangaprasad
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10933032-B2
Publication Date
2021-03-02
Expiration Date
Abstract
Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.
Core Innovation
The invention relates to methods of treating pancreatic cancer in a subject by administering coenzyme Q10 (CoQ10) in a treatment sequence coordinated with administration of gemcitabine or one or more chemotherapeutic agents. CoQ10 is administered by continuous intravenous infusion for at least 24 hours, and the subject is treated such that the overall treatment is improved relative to chemotherapy alone as described in the document.
A central aspect is the timing relationship between CoQ10 and the chemotherapeutic agent. The claims describe discontinuing CoQ10 administration prior to administering chemotherapy, administering chemotherapy after CoQ10 is initiated while continuing CoQ10 infusion, and pre-treating the subject with CoQ10 for a sufficient time prior to initiation of a chemotherapeutic treatment regimen.
Another central aspect is that CoQ10 is administered as a continuous intravenous infusion for a defined minimum duration and is combined with chemotherapeutic regimens in a way that improves the response. The described improvements are quantified as improved response relative to treatment with the chemotherapeutic treatment regimen alone, including percentage thresholds and representative response components such as reduction in tumor burden or reduction in tumor size, inhibition of tumor growth, stable oncological disorder, increased time to progression, and increased time of survival.
Claims Coverage
The independent claims cover four inventive features involving CoQ10 and chemotherapeutic treatment for pancreatic cancer with gemcitabine, including continuous intravenous infusion of CoQ10 and defined timing relationships relative to chemotherapy; one claim further requires a chemotherapeutic dosage lower than standard dosages.
Continuous CoQ10 infusion then discontinue before gemcitabine
Administering coenzyme Q10 (CoQ10) by continuous intravenous infusion for at least 24 hours; discontinuing administration of CoQ10; and administering at least one chemotherapeutic agent after administration with CoQ10 has been discontinued, wherein the chemotherapeutic agent comprises gemcitabine for pancreatic cancer treatment.
Continuous CoQ10 infusion with concurrent gemcitabine initiation
Administering CoQ10 by continuous intravenous infusion for at least 24 hours; administering at least one chemotherapeutic agent after administration of the CoQ10 is initiated; and continuing to administer CoQ10 by continuous intravenous infusion after administration of the at least one chemotherapeutic agent is initiated, wherein pancreatic cancer is treated and the at least one chemotherapeutic agent comprises gemcitabine.
CoQ10 pre-treatment to improve a gemcitabine regimen
Pre-treating a subject having pancreatic cancer with CoQ10 for a sufficient time prior to initiation of a chemotherapeutic treatment regimen such that a response is improved relative to treatment with the chemotherapeutic treatment regimen alone, wherein CoQ10 is administered by continuous intravenous infusion for at least 24 hours and the chemotherapeutic treatment regimen comprises gemcitabine.
Lower-than-standard gemcitabine dosage with continuous CoQ10 infusion
Administering coenzyme Q10 (CoQ10); and administering at least one chemotherapeutic agent at a dosage that is lower than standard dosages used to treat the oncological disorder, wherein CoQ10 is administered by continuous intravenous infusion for at least 24 hours, the oncological disorder is pancreatic cancer, and the at least one chemotherapeutic agent comprises gemcitabine.
Across the independent claims, the document covers pancreatic cancer treatment by coordinating continuous intravenous infusion of CoQ10 with gemcitabine-containing chemotherapy using discontinue-before, continue-through, or pre-treatment sequencing, and in one claim lowering the chemotherapeutic dosage compared with standard dosages.
Stated Advantages
Improved response relative to treatment with the chemotherapeutic treatment regimen alone, including quantified percentage improvement options.
Response characterized by reduced tumor burden or reduction in tumor size, inhibition of tumor growth, stable oncological disorder, increased time to progression, and increased time of survival.
Documented Applications
Treating pancreatic cancer in a subject using CoQ10 administered by continuous intravenous infusion in combination with gemcitabine-containing chemotherapeutic agents.
Improving a chemotherapeutic treatment regimen for pancreatic cancer by pre-treating a subject with CoQ10 administered by continuous intravenous infusion such that response is improved relative to the chemotherapeutic regimen alone.
Interested in licensing this patent?